All AbMole products are for research use only, cannot be used for human consumption.
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
| Molecular Weight | 948.04 |
| Formula | C35H57N13O14S2 |
| CAS Number | 1392278-76-0 |
| Solubility (25°C) | Water ≥ 50 mg/mL |
| Storage | -20°C, protect from light, dry, sealed |
[5] Hong Yin, et al. Mol Med Rep. iRGD as a tumor‑penetrating peptide for cancer therapy (Review)
| Related Integrin Products |
|---|
| MORF-627
MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC50 of 9.2 nM (measuring by human serum ligand binding assay). MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC50 of 8.3 nM. |
| Volociximab
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| GSK 3008348 hydrochloride
GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist. |
| HSDVHK-NH2
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
| LDV
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
